The new system is said to feature more than 50 improvements, including an advanced control body and a novel Lumox adaptive matrix imaging technology that provides physicians with better clarity.

Lumos Adaptive Matrix Imaging intends to improve the view of the mucosal structures and vascular patterns in their natural color and the ability for always-on functionality through smart enhancement technology.

The CE marked Lumos is available in the Europe. It still needs to secure approval in the US.

EndoChoice founder and CEO Mark Gilreath said: "We are truly excited to bring Fuse Generation 3 and Lumos to the world of GI. With Generation 3, not only do GI’s have an increased field of view to help detect lesions, they now have the ability to enhance anatomy like never before with Lumos Adaptive Matrix Imaging.

"We believe these advancements take the Fuse platform to an unprecedented level in endoscopic screening."

The company started started sales and distribution of third generation Fuse system in the US, European Union, and other select markets.

EndoChoice is showcasing the new Fuse system at the Digestive Disease Week (DDW) in San Diego of California, in addition to the SGNA 43rd Annual Course in Seattle of Washington. The meetings are taking place between 22 and 24 May.

Based in Atlanta of Georgia, EndoChoice manufactures and markets platform technologies, including endoscopic imaging systems, devices and infection control products.

It also offers pathology services for specialists to treat a wide range of gastrointestinal conditions, including colon cancer.

Image: The third-generation Fuse full spectrum endoscopy system. Photo: courtesy of EndoChoice, Inc.